Annual report [Section 13 and 15(d), not S-K Item 405]

Cover

v3.26.1
Cover - USD ($)
 12 Months Ended
Dec. 31, 2025
Mar. 11, 2026
Jun. 30, 2025
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2025    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2025    
Current Fiscal Year End Date --12-31    
Entity File Number 001-15771    
Entity Registrant Name ABEONA THERAPEUTICS INC.    
Entity Central Index Key 0000318306    
Entity Tax Identification Number 83-0221517    
Entity Incorporation, State or Country Code DE    
Entity Address, Address Line One 6555 Carnegie Avenue    
Entity Address, Address Line Two 4th Floor    
Entity Address, City or Town Cleveland    
Entity Address, State or Province OH    
Entity Address, Postal Zip Code 44103    
City Area Code (646)    
Local Phone Number 813-4701    
Title of 12(b) Security Common Stock, $0.01 par value    
Trading Symbol ABEO    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 273,252,724
Entity Common Stock, Shares Outstanding   57,049,023  
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Auditor Firm ID 34    
Auditor Opinion [Text Block] We have audited the accompanying consolidated balance sheets of Abeona Therapeutics Inc. and subsidiaries (the “Company”) as of December 31, 2025 and 2024, the related consolidated statements of operations and comprehensive income (loss), stockholders’ equity and cash flows, for each of the two years in the period ended December 31, 2025, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2025, in conformity with accounting principles generally accepted in the United States of America.    
Auditor Name Deloitte & Touche LLP    
Auditor Location Morristown, New Jersey